Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Thienopyridine (open-label) Clear all
Completed Phase 4 Interventional Results available

Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients

NCT01603082
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
16
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 4 Interventional

Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients

NCT01706510
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
Rapid City Regional Hospital, Inc
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rapid City, South Dakota
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 26, 2026, 1:46 AM EDT
Not listed Phase 4 Interventional

Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

NCT03150667
View directory record Official record
Conditions
Chronic Kidney Diseases, Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Durham, North Carolina • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Results available

Edoxaban in Peripheral Arterial Disease

NCT01802775
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
edoxaban, Clopidogrel, Aspirin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Results available

A Pharmacodynamic Study With Ticagrelor in Hispanic Patients

NCT01523366
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Los Angeles, California • Hollywood, Florida • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Results available

A Pharmacodynamic Study With Ticagrelor in African American Patients

NCT01523392
View directory record Official record
Conditions
Stable Coronary Artery Disease
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Newark, Delaware • Wilmington, Delaware • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2014 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects

NCT03430661
View directory record Official record
Conditions
Healthy
Interventions
ACT-246475, Clopidogrel, Prasugrel, Placebo, Ticagrelor
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Clopidogrel

NCT04671069
View directory record Official record
Conditions
Healthy
Interventions
MGL-3196, Clopidogrel
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 27, 2020 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

NCT04305587
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
PF-07081532, Placebo, Clopidogrel
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 4 Interventional Results available

Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty

NCT01121224
View directory record Official record
Conditions
Saphenous Vein Graft Atherosclerosis
Interventions
Bare Metal Stent, Drug-Eluting Stent, Blinded clopidogrel, Placebo, Thienopyridine (open-label)
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
25
States / cities
Tucson, Arizona • Little Rock, Arkansas • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Results available

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

NCT01830543
View directory record Official record
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg, aspirin (ASA), vitamin K antagonist (VKA), clopidogrel, prasugrel, ticagrelor
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
2,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
86
States / cities
Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2017 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

NCT00942175
View directory record Official record
Conditions
Healthy
Interventions
Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

NCT01147588
View directory record Official record
Conditions
Healthy
Interventions
lansoprazole, omeprazole, esomeprazole, clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Sep 26, 2026, 1:46 AM EDT
Terminated Phase 4 Interventional Results available

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

NCT02052635
View directory record Official record
Conditions
Non-ST Elevation Acute Coronary Syndrome
Interventions
ticagrelor, clopidogrel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Jacksonville, Florida • Lake Mary, Florida • Macon, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

NCT02164864
View directory record Official record
Conditions
Atrial Fibrillation, Percutaneous Coronary Intervention
Interventions
Dabigatran Etexilate 110mg, Warfarin 3mg, Aspirin, Dabigatran Etexilate 150mg, Clopidogrel or Ticagrelor, Warfarin 5mg, Warfarin 1mg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
2,725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
45
States / cities
Birmingham, Alabama • Cottonwood, Arizona • Mesa, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 26, 2026, 1:46 AM EDT
Withdrawn Phase 4 Interventional

Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis

NCT02048085
View directory record Official record
Conditions
Acute ST Segment Elevation Myocardial Infarction, Acute Coronary Syndrome
Interventions
Ticagrelor, Clopidogrel
Drug
Lead sponsor
Medical Center of South Arkansas
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
El Dorado, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events

NCT01586975
View directory record Official record
Conditions
Stroke, Myocardial Infarctions
Interventions
Clopidogrel, Aspirin 81 mg, Aspirin >300 mg
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 2 Interventional Results available

Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event

NCT00356135
View directory record Official record
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
prasugrel 10 mg, clopidogrel, prasugrel placebo, prasugrel 60 mg, clopidogrel placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Jacksonville, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study

NCT01768637
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Aspirin, Clopidogrel
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 90 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Chronic Kidney Disease (CKD) Platelet Study

NCT03649711
View directory record Official record
Conditions
Chronic Kidney Diseases, Heart Attack, Stroke, Ischemic
Interventions
Ticagrelor 90mg, Clopidogrel 75mg, Aspirin 81 mg
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 91 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets

NCT01744288
View directory record Official record
Conditions
Inhibition on Platelet Aggregation
Interventions
Ticagrelor, Clopidogrel, ASA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Platlet Aggregation of Clopidogrel, EC Aspirin 81 mg, EC Omeprazole 40 mg Compare to PA32540

NCT01557335
View directory record Official record
Conditions
Platelet Aggregation
Interventions
Plavix® and PA32540, EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)
Drug
Lead sponsor
POZEN
Industry
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamics of CGT 2168 Compared With Plavix®

NCT00620802
View directory record Official record
Conditions
Healthy
Interventions
CGT-2168, Plavix
Drug
Lead sponsor
Cogentus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2008 · Synced Sep 26, 2026, 1:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers

NCT05162053
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
vicagrel Capsules, Clopidogrel Tablets
Drug
Lead sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Sep 26, 2026, 1:46 AM EDT